Eurofins Viracor BioPharma Immunotherapy Force Multiplier
It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.
Exploring the application of comprehensive genomic profiling in oncology therapy development.
Eurofins Viracor invites you to add the upcoming event to your calendar. This informative webinar; featuring Karina Eterovic, PhD, R&D Director of Oncology Diagnostics at Eurofins Viracor, entitled: Exploring the application of comprehensive genomic profiling in oncology therapy development.
Optimizing Flow Cytometry Quantitation of Rare-Cell Populations and Its Application In Immunotherapy
Eurofins Viracor invites you to add the upcoming event to your calendar. This informative webinar, featuring our flow cytometry expert, Dr. Brian Maybruck, will focus on the use of Flow Cytometry for rare cell quantitation, and its application in drug development.
Multiparameter flow cytometry applications and future outlook
Flow cytometry is a very powerful and reliable alternative to many other methods used for clinical drug development. Consider that it can simultaneously measure multiple parameters on tens of thousands of cells, with a resolution down to a single cell level, robustly and rapidly (greater than 1000 samples per day).